Targeting the aryl hydrocarbon receptor as a strategy to expand the therapeutic armamentarium in atopic dermatitis

References

• Eichenfield LF, Stein Gold LF. Practical strategies for the diagnosis and assessment of atopic dermatitis. Semin Cutan Med Surg. 2017;36(2 Suppl 2):1–5. doi:10.12788/j.sder.2017.009.
   PubMedGoogle Scholar
• Birdi G, Cooke R, Knibb RC. Impact of atopic dermatitis on quality of life in adults: a systematic review and meta- analysis. Int J Dermatology. 2020;59(4):e75–e91. doi:10.1111/ijd.14763.
   PubMed Web of Science ®Google Scholar
• Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic dermatitis in america study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population. J Invest Dermatol. 2019;139(3):583–590. doi:10.1016/j.jid.2018.08.028.
   PubMed Web of Science ®Google Scholar
• Laughter D, Istvan JA, Tofte SJ, et al. The prevalence of atopic dermatitis in Oregon schoolchildren. J Am Acad Dermatol. 2000;43(4):649–655. doi:10.1067/mjd.2000.107773.
   PubMed Web of Science ®Google Scholar
• Shaw TE, Currie GP, Koudelka CW, et al. Eczema prevalence in the United States: data from the 2003 national survey of children’s health. J Invest Dermatol. 2011;131(1):67–73. doi:10.1038/jid.2010.251.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Simpson EL. Associations of childhood eczema severity: a US population-based study. Dermatitis. 2014;25(3):107–114. doi:10.1097/DER.0000000000000034.
   PubMed Web of Science ®Google Scholar
• Laughter MR, Maymone MBC, Mashayekhi S, et al. The global burden of atopic dermatitis: lessons from the global burden of disease study 1990–2017. Br J Dermatol. 2021;184(2):304–309. doi:10.1111/bjd.19580.
   PubMed Web of Science ®Google Scholar
• Drucker AM, Wang AR, Li WQ, et al. The burden of atopic dermatitis: summary of a report for the national eczema association. J Invest Dermatol. 2017;137(1):26–30. doi:10.1016/j.jid.2016.07.012.
   PubMed Web of Science ®Google Scholar
• Wang X, Boytsov NN, Gorritz M, et al. US health care utilization and costs in adult patients with atopic dermatitis by disease severity. J Manag Care Spec Pharm. 2022;28(1):69–77. doi:10.18553/jmcp.2022.28.1.69.
   PubMed Web of Science ®Google Scholar
• Bieber T. Atopic dermatitis: an expanding therapeutic pipeline for a complex disease. Nat Rev Drug Discov. 2022;21(1):21–40. doi:10.1038/s41573-021-00266-6.
   PubMed Web of Science ®Google Scholar
• Vakharia PP, Silverberg JI. Adult-onset atopic dermatitis: characteristics and management. Am J Clin Dermatol. 2019;20(6):771–779. doi:10.1007/s40257-019-00453-7.
   PubMed Web of Science ®Google Scholar
• Carroll CL, Balkrishnan R, Feldman SR, et al. The burden of atopic dermatitis. Impact on the patient, family, and society. Pediatr Dermatol. 2005;22(3):192–199. doi:10.1111/j.1525-1470.2005.22303.x.
   PubMed Web of Science ®Google Scholar
• LeBovidge JS, Kelley SD, Lauretti A, et al. Integrating medical and psychological health care for children with atopic dermatitis. J Pediatr Psychol. 2007;32(5):617–625. doi:10.1093/jpepsy/jsl045.
   PubMed Web of Science ®Google Scholar
• Meltzer LJ, Flewelling KD, Jump S, et al. Impact of atopic dermatitis treatment on child and parent sleep, daytime functioning, and quality of life. Ann Allergy Asthma Immunol. 2020;124(4):385–392. doi:10.1016/j.anai.2019.12.024.
   PubMed Web of Science ®Google Scholar
• Pan Z, Dai Y, Akar-Ghibril N, et al. Impact of air pollution on atopic dermatitis: a comprehensive review. Clin Rev Allergy Immunol. 2023;65(2):121–135. doi:10.1007/s12016-022-08957-7.
   PubMed Web of Science ®Google Scholar
• Abuabara K, Margolis DJ, Langan SM. The long-term course of atopic dermatitis. Dermatol Clin. 2017;35(3):291–297. doi:10.1016/j.det.2017.02.003.
   PubMed Web of Science ®Google Scholar
• Suárez-Fariñas M, Dhingra N, Gittler J, et al. Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013;132(2):361–370. doi:10.1016/j.jaci.2013.04.046.
   PubMed Web of Science ®Google Scholar
• Thijs JL, de Bruin-Weller MS, Hijnen D. Current and future biomarkers in atopic dermatitis. Immunol Allergy Clin North Am. 2017;37(1):51–61. doi:10.1016/j.iac.2016.08.008.
   PubMed Web of Science ®Google Scholar
• Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta- analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. J Am Acad Dermatol. 2019;80(2):390–401. doi:10.1016/j.jaad.2018.09.035.
   PubMed Web of Science ®Google Scholar
• Bieber T. Disease modification in inflammatory skin disorders: opportunities and challenges. Nat Rev Drug Discov. 2023;22(8):662–680. doi:10.1038/s41573-023-00735-0.
   PubMed Web of Science ®Google Scholar
• Davidson WF, Leung DY, Beck LA, et al. Report from the national institute of allergy and infectious diseases workshop on "atopic dermatitis and the atopic march: mechanisms and interventions. J Allergy Clin Immunol. 2019;143(3):894–913. doi:10.1016/j.jaci.2019.01.003.
   PubMed Web of Science ®Google Scholar
• Feldman SR, Cox LS, Strowd LC, et al. The challenge of managing atopic dermatitis in the United States. Am Health Drug Benefits. 2019;12:83–93.
   PubMed Web of Science ®Google Scholar
• FDA Tralokinumab-ldrm (ADBRY™) Prescribing Information. 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761180s001lbl.pdf
   Google Scholar
• FDA. Dupilumab (DUPIXENT®) Prescribing Information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/761055s042lbl.pdf
   Google Scholar
• FDA. Abrocitinib (CIBINQO™). Prescribing Information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/213871s000lbl.pdf
   Google Scholar
• FDA. Upadacitinib (RINVOQ®) Prescribing Information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/211675s003lbl.pdf
   Google Scholar
• FDA. Crisaborole (EUCRISA™) Prescribing Information. 2020. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/207695s007s009s010lbl.pdf
   Google Scholar
• FDA. Ruxolitinib (OPZELURA™) Prescribing Information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215309s001lbl.pdf
   Google Scholar
• FDA. Pimecrolimus (ELIDEL®) Prescribing Information. 2014. https://www.accessdata.fda.gov/drugsatfda_docs/label/2014/021302s018lbl.pdf
   Google Scholar
• FDA. Tacrolimus (PROTOPIC®) Prescribing Information. 2011. https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/050777s018lbl.pdf
   Google Scholar
• Ruer-Mulard M, Aberer W, Gunstone A, et al. Twice-daily versus once-daily applications of pimecrolimus cream 1% for the prevention of disease relapse in pediatric patients with atopic dermatitis. Pediatr Dermatol. 2009;26(5):551–558. doi:10.1111/j.1525-1470.2009.00981.x.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Gower RG, Xu J, et al. Once-daily crisaborole ointment, 2%, as a long-term maintenance treatment in patients aged ≥ 3 months with mild-to-moderate atopic dermatitis: a 52-week clinical study. Am J Clin Dermatol. 2023;24(4):623–635. doi:10.1007/s40257-023-00780-w.
   PubMed Web of Science ®Google Scholar
• FDA. Tapinarof (VTAMA®) cream Prescribing Information. 2022. https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215272s000lbl.pdf
   Google Scholar
• Silverberg JI, Eichenfield LF, Hebert AA, et al. Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in two pivotal phase 3 trials in adults and children down to 2 years of age. In: Late breaking news oral presentation at the European academy of dermatology and venereology, Berlin, Germany, 2023.
   Google Scholar
• Simpson EL, Silverberg JI, Bissonnette R, et al. Rapid and early onset of itch relief with tapinarof cream 1% once daily in two pivotal phase 3 trials in adults and children down to two years of age with moderate to severe atopic dermatitis. In: Late breaking news oral presentation at the european academy of dermatology and venereology., Berlin, Germany, 2023.
   Google Scholar
• Bissonnette R, Gold LS, Rubenstein DS, et al. Tapinarof in the treatment of psoriasis: a review of the unique mechanism of action of a novel therapeutic aryl hydrocarbon receptor–modulating agent. J Am Acad Dermatol. 2021;84(4):1059–1067. doi:10.1016/j.jaad.2020.10.085.
   PubMed Web of Science ®Google Scholar
• Di Meglio P, Duarte JH, Ahlfors H, et al. Activation of the aryl hydrocarbon receptor dampens the severity of inflammatory skin conditions. Immunity. 2014;40(6):989–1001. doi:10.1016/j.immuni.2014.04.019.
   PubMed Web of Science ®Google Scholar
• Esser C, Rannug A. The aryl hydrocarbon receptor in barrier organ physiology, immunology, and toxicology. Pharmacol Rev. 2015;67(2):259–279. doi:10.1124/pr.114.009001.
   PubMed Web of Science ®Google Scholar
• Furue M, Hashimoto-Hachiya A, Tsuji G. Aryl hydrocarbon receptor in atopic dermatitis and psoriasis. Int J Mol Sci. 2019;20(21):5424. doi:10.3390/ijms20215424.
   PubMed Web of Science ®Google Scholar
• Furue M, Tsuji G, Mitoma C, et al. Gene regulation of filaggrin and other skin barrier proteins via aryl hydrocarbon receptor. J Dermatol Sci. 2015;80(2):83–88. doi:10.1016/j.jdermsci.2015.07.011.
   PubMed Web of Science ®Google Scholar
• Furue M. Regulation of filaggrin, loricrin, and involucrin by IL-4, IL-13, IL-17A, IL-22, AHR, and NRF2: pathogenic implications in atopic dermatitis. Int J Mol Sci. 2020;21(15):5382. doi:10.3390/ijms21155382.
   PubMed Web of Science ®Google Scholar
• Mooney N, Teague J, Gehad A, et al. Tapinarof inhibits the formation, cytokine production, and persistence of resident memory T cells in vitro. J of Skin. 2023;7(2):s194. doi:10.25251/skin.7.supp.194.
   Google Scholar
• Smith SH, Jayawickreme C, Rickard DJ, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137(10):2110–2119. doi:10.1016/j.jid.2017.05.004.
   PubMed Web of Science ®Google Scholar
• Sutter CH, Azim S, Wang A, et al. Ligand activation of the aryl hydrocarbon receptor upregulates epidermal uridine diphosphate glucose ceramide glucosyltransferase and glucosylceramides. J Invest Dermatol. 2023;143(10):1964–1972.e4. doi:10.1016/j.jid.2023.03.1662.
   PubMed Web of Science ®Google Scholar
• Strober B, Gold LS, Bissonnette R, et al. One-year safety and efficacy of tapinarof cream for the treatment of plaque psoriasis: results from the PSOARING 3 trial. J Am Acad Dermatol. 2022;87(4):800–806. doi:10.1016/j.jaad.2022.06.1171.
   PubMed Web of Science ®Google Scholar
• Jett JE, McLaughlin M, Lee MS, et al. Tapinarof cream 1% for extensive plaque psoriasis: a maximal use trial on safety, tolerability, and pharmacokinetics. Am J Clin Dermatol. 2022;23(1):83–91. doi:10.1007/s40257-021-00641-4.
   PubMed Web of Science ®Google Scholar